Pfizer Stock Is Plunging Today - What's Going On
Pfizer Stock Is Plunging Today - What's Going On
$Pfizer (PFE.US)$ has decided to continue the clinical development of the oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate, danuglipron (PF-06882961), for adults with obesity and Type 2 diabetes mellitus.
$輝瑞 (PFE.US)$ 已決定繼續臨床開發用於肥胖和2型糖尿病成人的口服晚期胰高血糖素樣肽-1受體激動劑（GLP-1-RA）候選藥物danuglipron（PF-06882961）。
The company plans to discontinue the clinical development of another GLP-1-RA candidate, lotiglipron (PF-07081532), due to pharmacokinetic data from Phase 1 studies and laboratory measurements of elevated transaminases (liver enzymes).
由於來自第一階段研究的藥代動力學數據和轉氨酶（肝酶）升高的實驗室測量，該公司計劃停止另一種 GLP-1-RA 候選藥物lotiglipron（PF-07081532）的臨床開發。
None of the participants reported liver-related symptoms, and there was no evidence of liver failure or need for treatment.
沒有參與者報告肝臟相關症狀，也沒有證據表明肝衰竭或需要治療。
The announcement is "incrementally negative for perception" around Pfizer's weight loss drugs, Reuters noted, citing SVB Securities analyst David Risinger.
路透社援引說，這一宣佈 “對輝瑞減肥藥物的看法越來越消極” SVB 證券 分析師大衛·裏辛格。
Demand for Wegovy and Ozempic from Novo Nordisk A/S (NYSE:NVO) for treating obesity and diabetes, respectively, has soared recently.
對 Wegovy 和 Ozempic 的需求來自 Novo Nordisk A/S 分別用於治療肥胖和糖尿病的紐約證券交易所代碼：NVO）最近飆升。
The demand for treatments like Wegovy could support as many as ten competing products, with annual sales reaching up to $100 billion within a decade, mostly in the U.S., industry executives and analysts have said.
行業高管和分析師表示，對像Wegovy這樣的治療方法的需求可能支持多達十種競爭產品，年銷售額在十年內達到1000億美元，主要在美國。
Plans for the late-stage program of danuglipron are expected to be finalized by the end of 2023. The company is also working on a once-daily modified-release version of this drug.
danuglipron後期計劃的計劃預計將在2023年底之前最終確定。該公司還在研究這種藥物的每日一次的修改釋放版本。
Previously published results from the Phase 2 study of danuglipron in T2DM showed dose-dependent placebo-adjusted reductions in HbA1c, fasting plasma glucose, and body weight over 16 weeks.
先前公佈的T2DM中danuglipron的2期研究結果顯示，在16周內，Hba1c、空腹血糖和體重的劑量依賴性安慰劑調整後會降低。
The most common adverse events reported in this study were nausea, vomiting, and diarrhea.
本研究報告的最常見的不良事件是噁心、嘔吐和腹瀉。
The ongoing Phase 2b study of danuglipron in non-diabetic obesity participants is expected to complete by the end of the year.
正在進行的針對非糖尿病肥胖參與者的danuglipron的2b期研究預計將於今年年底完成。
Elevated transaminase levels have not been observed in the over 1,400 patients enrolled in the danuglipron program.
在參加danuglipron計劃的1400多名患者中，尚未觀察到轉氨酶水平升高。